NOTICE: Silverback Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

SAN DIEGO, CA / ACCESSWIRE / November 26, 2021 / Robbins Geller Rudman & Dowd LLP announces that buyers of: (1) common stock of Silverback Therapeutics Inc. (NASDAQ: SBTX) as set out in the offering documents in connection with Silverback Therapeutics’ initial public offering on or about the 3rd “); and / or (2) securities of Silverback Therapeutics between December 3, 2020 and September 10, 2021, both days inclusive (the “Classification Period”) through January 4, 2022, to apply for lead plaintiff in the Dresner v. Silverback Therapeutics, Inc. , No. 21-cv-01499 (WD Wash.). Silverback Therapeutics’ class action lawsuit, which began November 5, 2021 and was assigned to Judge Theresa L Fricke, charges Silverback Therapeutics and some of its officers and directors with violations of the Securities Act of 1933 and / or the Securities Exchange Act of 1934.

If you are the Silverback Therapeutics Class action, please Provide your information by clicking here. You can also contact a lawyer JC Sanchezfrom Robbins Geller by phone at 800 / 449-4900 or by email at [email protected]. Main plaintiff motions for the Silverback Therapeutics The class action lawsuit must be filed in court no later than January 4, 2022.

CASE ALLEGATIONS: Silverback Therapeutics’ lead product candidate is SBT6050, which is in a Phase 1 / 1b clinical trial of lung cancer. On November 10, 2020, Silverback Therapeutics announced in connection with its initial public offering, following several changes on November 3rd, 2020. On or about December 3rd, 2020, Silverback Therapeutics’ common stock was listed on the Nasdaq Global Market (“NASDAQ”) under the ticker symbol “SBTX” traded. As of its IPO, Silverback Therapeutics has 11.5 million shares of common stock at a price of $ 21.00 per share.

The story goes on

The Silverback Therapeutics class action alleges that the offering documents and defendants made false and misleading statements during the class action period and did not disclose that: (i) Silverback Therapeutics’ lead product candidate, SBT6050, was less effective than Silverback Therapeutics presented to investors would have; (ii) accordingly, Silverback Therapeutics had overstated the commercial and / or clinical prospects of SBT6050; and (iii) as a result, Defendants’ offer documents and public statements during the Class Action Period were materially inaccurate and / or misleading and did not contain any required information.

On September 13, 2021, Silverback Therapeutics published an “announce” press release[ing] that preliminary data from the dose escalation portion of its Phase 1 / 1b clinical trial evaluating SBT6050 as monotherapy and in combination with pembrolizumab in patients with advanced or metastatic HER2-expressing or amplified solid tumors will be presented at the upcoming European Society for Medical Oncology (ESMO ) 2021 Congress from 16.-21. September 2021 “and indicates that”[t]he accepted abstractly. . . is now available on the ESMO website. “According to the accepted abstract, while SBT6050 gave a manageable safety profile for Silverback Therapeutics’ experimental therapy, it showed only partial response among 14 HER2-positive solid tumors, which fell more than 23% When the Silverback Therapeutics class action lawsuit was filed, Silverback Therapeutics’ common stock continued to trade below the IPO of $ 21.00 per share.

THE LEAD APPLICANT PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who has acquired: (1) Silverback Therapeutics common stock pursuant to the offering documents issued and / or attributable to Silverback Therapeutics’ initial public offering; and / or (2) Silverback Therapeutics ‘securities during the class action period to seek appointment as lead plaintiff in Silverback Therapeutics’ class action. A lead plaintiff is usually the applicant with the greatest financial interest in the legal protection sought by the alleged class, which is also typical and appropriate for the alleged class. One lead plaintiff is acting on behalf of all of the other class plaintiffs in directing the Silverback Therapeutics class action. The lead plaintiff can select a law firm of their choice to bring the Silverback Therapeutics class action lawsuit. An investor’s ability to participate in a possible future collection of Silverback Therapeutics’ class action lawsuit does not depend on whether or not they act as the lead plaintiff.

ABOUT ROBBINS GELLER RUDMAN & DOWD LLP: With 200 attorneys in 9 offices across the country, Robbins Geller Rudman & Dowd LLP is the largest US law firm serving investors in securities class actions. Robbins Geller’s attorneys have secured many of the largest shareholder reclaims in history, including the largest securities class action of all time – $ 7.2 billion – in In re Enron Corp. Sec. Lit. The 2020 ISS Securities Class Action Services Top 50 Report ranked Robbins Geller first for getting $ 1.6 billion back for investors last year, more than double the amount paid by any other securities plaintiff firm was drafted. More information is available at http://www.rgrdlaw.com.

Lawyer advertising.
Past results do not guarantee future results.
Services can be performed by lawyers in any of our offices.

CONTACT:
Robbins Geller Rudman & Dowd LLP
655 W. Broadway, San Diego, CA 92101
JC Sanchez, 800-449-4900
[email protected]

SOURCE: Robbins Geller Rudman & Dowd LLP

View source version on accesswire.com:
https://www.accesswire.com/674438/NOTICE-Silverback-Therapeutics-Inc-Investors-with-Substantial-Losses-Have-Opportunity-to-Lead-Class-Action-Lawsuit–SBTX

Comments are closed.